» Articles » PMID: 36173746

Combined Structural Analysis and Molecular Dynamics Reveal Penicillin-Binding Protein Inhibition Mode with β-Lactones

Overview
Journal ACS Chem Biol
Specialties Biochemistry
Biology
Date 2022 Sep 29
PMID 36173746
Authors
Affiliations
Soon will be listed here.
Abstract

β-Lactam antibiotics comprise one of the most widely used therapeutic classes to combat bacterial infections. This general scaffold has long been known to inhibit bacterial cell wall biosynthesis by inactivating penicillin-binding proteins (PBPs); however, bacterial resistance to β-lactams is now widespread, and new strategies are urgently needed to target PBPs and other proteins involved in bacterial cell wall formation. A key requirement in the identification of strategies to overcome resistance is a deeper understanding of the roles of the PBPs and their associated proteins during cell growth and division, such as can be obtained with the use of selective chemical probes. Probe development has typically depended upon known PBP inhibitors, which have historically been thought to require a negatively charged moiety that mimics the C-terminus of the PBP natural peptidoglycan substrate, d-Ala-d-Ala. However, we have identified a new class of β-lactone-containing molecules that interact with PBPs, often in an isoform-specific manner, and do not incorporate this C-terminal mimetic. Here, we report a series of structural biology experiments and molecular dynamics simulations that we utilized to evaluate specific binding modes of this novel PBP inhibitor class. In this work, we obtained <2 Å resolution X-ray structures of four β-lactone probes bound to PBP1b from . Despite their diverging recognition modes beyond the site of covalent modification, these four probes all efficiently labeled PBP1b, as well as other PBPs from . . From these structures, we analyzed protein-ligand interactions and characterized the β-lactone-bound active sites using mutagenesis and molecular dynamics. Our approach has clarified the dynamic interaction profile in this series of ligands, expanding the understanding of PBP inhibitor binding.

Citing Articles

Drug Discovery in the Field of β-Lactams: An Academic Perspective.

Jacobs L, Consol P, Chen Y Antibiotics (Basel). 2024; 13(1).

PMID: 38247618 PMC: 10812508. DOI: 10.3390/antibiotics13010059.


Penicillin-binding protein (PBP) inhibitor development: A 10-year chemical perspective.

Bertonha A, Silva C, Shirakawa K, Trindade D, Dessen A Exp Biol Med (Maywood). 2023; 248(19):1657-1670.

PMID: 38030964 PMC: 10723023. DOI: 10.1177/15353702231208407.


Activity-based protein profiling in microbes and the gut microbiome.

Han L, Chang P Curr Opin Chem Biol. 2023; 76:102351.

PMID: 37429085 PMC: 10527501. DOI: 10.1016/j.cbpa.2023.102351.


β-Lactams from the Ocean.

Fisher J, Mobashery S Mar Drugs. 2023; 21(2).

PMID: 36827127 PMC: 9963991. DOI: 10.3390/md21020086.

References
1.
Macheboeuf P, Fischer D, Brown Jr T, Zervosen A, Luxen A, Joris B . Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nat Chem Biol. 2007; 3(9):565-9. DOI: 10.1038/nchembio.2007.21. View

2.
Kumarasiri M, Zhang W, Shi Q, Fisher J, Mobashery S . Protonation states of active-site lysines of penicillin-binding protein 6 from Escherichia coli and the mechanistic implications. Proteins. 2013; 82(7):1348-58. PMC: 4057297. DOI: 10.1002/prot.24501. View

3.
Contreras-Martel C, Martins A, Ecobichon C, Trindade D, Mattei P, Hicham S . Molecular architecture of the PBP2-MreC core bacterial cell wall synthesis complex. Nat Commun. 2017; 8(1):776. PMC: 5626683. DOI: 10.1038/s41467-017-00783-2. View

4.
Emsley P, Cowtan K . Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. DOI: 10.1107/S0907444904019158. View

5.
Kabsch W, Sander C . Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983; 22(12):2577-637. DOI: 10.1002/bip.360221211. View